Medtronic Begins Active Portfolio Management Phase

Medtronic reported FY 3Q22 orthopedic sales of $793 million, +7.1% vs. FY 3Q21. Broad-based omicron-related absenteeism peaked in mid-January, and company leadership said that trends improved in February. However, healthcare worker shortages are expected to remain a pressure throughout the year.

The company anticipates that China could...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0